Skip header and navigation

1 records – page 1 of 1.

Use of lipid-lowering drugs during 1991-98 in Northern Jutland, Denmark.
Br J Clin Pharmacol. 2001 Sep;52(3):307-11
Publication Type
S. Riahi
K. Fonager
E. Toft
L. Hvilsted-Rasmussen
J. Bendsen
S. Paaske Johnsen
H T Sørensen
Author Affiliation
Department of Cardiology, Aalborg Hospital, Aalborg, Denmark.
Br J Clin Pharmacol. 2001 Sep;52(3):307-11
Publication Type
Age Factors
Denmark - epidemiology
Drug Therapy - statistics & numerical data
Hyperlipidemias - drug therapy - epidemiology
Hypolipidemic Agents - therapeutic use
Middle Aged
Sex Factors
To examine a) the use of lipid-lowering drugs in North Jutland County in Denmark from 1991 to 1998 and b) the pattern of usage according to sex and age.
We used the Pharmaco-Epidemiological Prescription Database in the county to identify all reimbursed prescriptions for lipid-lowering therapy from 1991 to 1998. One-year incidence rates (IR) and prevalence (P) of the use of lipid-lowering drugs were calculated. Both IR and P of patients in lipid-lowering therapy were stable until 1994, with the IR below 100 per 100 000 for both sexes. The IR then increased from 59.9 to 236.5 per 100 000 person-years in 1998 for women, and from 88.6 to 322.8 per 100 000 person-years for men. The utilization patterns were identical between the sexes. Thus, in both women and men the highest prevalence and incidence rates of lipid-lowering drug therapy were seen in the 60-69-year-olds. Furthermore, the marked increase in both prevalence and incidence of persons on lipid-lowering drug therapy between 1994 and 1998 was the result of an increased number of prescriptions in the 50-59, 60-69 and 70 + years olds, in both women and men. There was a remarkable 4-5 fold increase in the numbers of new patients who received statins during the same period.
The overall use of lipid-lowering drugs has increased markedly over the last few years in Northern Jutland, Denmark. The increase began following publication of the first major trial documenting the benefit of therapy with statins.
Cites: Br J Clin Pharmacol. 2000 May;49(5):463-7110792204
Cites: Am J Med. 2000 Apr 15;108(6):496-910781783
Cites: BMJ. 2000 Oct 21;321(7267):983-611039962
Cites: JAMA. 1986 Nov 28;256(20):2823-83773199
Cites: JAMA. 1986 Nov 28;256(20):2835-83773200
Cites: BMJ. 1991 Aug 3;303(6797):276-821888927
Cites: JAMA. 1992 Jul 8;268(2):240-81535110
Cites: BMJ. 1994 Feb 5;308(6925):363-68124143
Cites: BMJ. 1994 Jun 4;308(6942):1488-928019284
Cites: JAMA. 1994 Nov 2;272(17):1335-407772105
Cites: Lancet. 1994 Nov 19;344(8934):1383-97968073
Cites: N Engl J Med. 1995 Apr 27;332(17):1125-317700285
Cites: JAMA. 1995 Aug 16;274(7):539-447629981
Cites: N Engl J Med. 1995 Nov 16;333(20):1301-77566020
Cites: Am J Cardiol. 1999 May 1;83(9):1303-710235085
Cites: Lancet. 1996 Feb 24;347(9000):551-28596304
Cites: Arch Intern Med. 1996 Oct 14;156(18):2085-928862101
Cites: J Am Coll Cardiol. 1997 Jan;29(1):139-468996306
Cites: Hypertension. 1997 May;29(5):1091-49149671
Cites: JAMA. 1997 Jul 23-30;278(4):313-219228438
Cites: Eur J Clin Pharmacol. 1997;53(3-4):185-99476029
Cites: Circulation. 1998 Apr 21;97(15):1440-59576423
Cites: JAMA. 1998 May 13;279(18):1458-629600480
Cites: JAMA. 1998 May 27;279(20):1615-229613910
Cites: Arch Intern Med. 1998 Jun 8;158(11):1238-449625403
Cites: J Am Coll Cardiol. 1998 Jul;32(1):140-69669262
Cites: Arch Intern Med. 1998 Sep 14;158(16):1761-89738605
Cites: BMJ. 1998 Oct 24;317(7166):1134-59784452
Cites: N Engl J Med. 1998 Nov 5;339(19):1349-579841303
Cites: Eur Heart J. 1998 Oct;19(10):1434-5039820987
Cites: JAMA. 1999 Dec 22-29;282(24):2340-610612322
Cites: Arch Intern Med. 2000 Feb 14;160(3):343-710668836
Cites: BMJ. 2000 Jun 10;320(7249):1583-410845969
PubMed ID
11560563 View in PubMed
Less detail